×
DexCom Receivables 2010-2024 | DXCM
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
DexCom receivables for the quarter ending September 30, 2024 were
$1.002B
, a
27.53% increase
year-over-year.
DexCom receivables for 2023 were
$0.974B
, a
36.53% increase
from 2022.
DexCom receivables for 2022 were
$0.713B
, a
38.69% increase
from 2021.
DexCom receivables for 2021 were
$0.514B
, a
20.02% increase
from 2020.
View More
DexCom Receivables 2010-2024 | DXCM
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
DexCom receivables for 2023 were
$0.974B
, a
36.53% increase
from 2022.
DexCom receivables for 2022 were
$0.713B
, a
38.69% increase
from 2021.
DexCom receivables for 2021 were
$0.514B
, a
20.02% increase
from 2020.
Related Stocks
Company Name
Market
Cap
Thermo Fisher Scientific (TMO)
$211B
Intuitive Surgical (ISRG)
$191.1B
Alcon (ALC)
$45.7B
IQVIA Holdings (IQV)
$39.8B
Edwards Lifesciences (EW)
$39.1B
IDEXX Laboratories (IDXX)
$35.5B
Waters (WAT)
$22.8B
SONOVA HOLDING (SONVY)
$22.1B
STERIS (STE)
$21.6B
Hologic (HOLX)
$18.3B
Sysmex ADR (SSMXY)
$12.9B
Fresenius Medical Care AG KGaA (FMS)
$12.5B
Globus Medical (GMED)
$11B
Teleflex (TFX)
$9.1B
Penumbra (PEN)
$9.1B
Masimo (MASI)
$8.7B
Glaukos (GKOS)
$7.8B
PROCEPT BioRobotics (PRCT)
$5.2B
Integer Holdings (ITGR)
$4.6B
Inari Medical (NARI)
$3B
TransMedics (TMDX)
$2.9B
LivaNova (LIVN)
$2.8B
Veracyte (VCYT)
$2.8B
Nihon Kohden (NHNKY)
$2.6B
Elekta AB (EKTAY)
$2.3B
Tandem Diabetes Care (TNDM)
$2B
Integra LifeSciences Holdings (IART)
$1.9B
RxSight (RXST)
$1.8B
Alphatec Holdings (ATEC)
$1.3B
Pulse Biosciences (PLSE)
$1.2B